First Quarter 2018 Investor Presentation
Investor Presentation
First three months of 2018
Slide 64
Significant growth in GLP-1 market with leading market
share for VictozaⓇ
Global GLP-1 market value and share of total
diabetes care market value
exenatide
Novo Nordisk GLP-1 value market share
leading in all regions except Japan & Korea
☐ Novo Nordisk GLP-1 value market share
VictozaⓇ
DKK
billion
albiglutide1
70
60
50
exenatide
launch
40
30
20
10
2005
dulaglutide
lixisenatide
GLP-1 share of total
diabetes care market
DKK
billion
FDA/EMA statement on
14%
60
47%
pancreatic safety³
12%
50
Dulaglutide
Article on
launch
10%
pancreatic safety
40
of incretins²
- 8%
30
VICTOZA
- 6%
liraglutide injection
20
- 4%
- 2%
10
57%
38%
73%
47%
72%
0%
0
2009
2013 2014
2018
North
America
Region Region Region Region
Europe J&K LATAM AAMEO
Region
China
1 Manufacturing and sale of albiglutide to be discontinued by Jul 2018
2 Butler et al, Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans
With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine
Tumors, Diabetes, Vol. 62, Jul 2013'
3 Egan et al, Pancreatic Safety of Incretin-Based Drugs - FDA and EMA Assessment, The New England
Journal of Medicine 370;9, 27 Feb 2014
Source: IQVIA MIDAS, monthly data, Feb 2018 (Note: IQVIA data does not adequately capture rebates
resulting in an overstatement of market value)
FDA: US Food and Drug Administration; EMA: European Medicines Agency
AAMEO: Africa, Asia, Middle-East and Oceania; J&K: Japan & Korea; LATAM: Latin America
Source: Reported sales until Feb 2018; IQVIA MIDAS, Feb 2018
novo nordiskView entire presentation